On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

MPL

MPL proto-oncogene, thrombopoietin receptor

The MPL gene provides instructions for producing the thrombopoietin receptor, a protein critical for the development and proliferation of blood cells, particularly megakaryocytes which produce platelets. MPL encodes the thrombopoietin receptor, a cell surface protein that plays a vital role in haematopoiesis, the process of blood cell formation.

Chromosome 1p34.2 Autosomal recessive HGNC:7217 Tier C
MPL 1p34.2 p arm q arm 1

MPL is located on the short (p) arm of chromosome 1, at band 1p34.2. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 1 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The MPL gene, also known as myeloproliferative leukaemia protein, contains the genetic instructions for the thrombopoietin receptor. This receptor is a crucial component in regulating blood cell production, especially for megakaryocytes and platelets. Abnormalities in MPL can result in various haematological conditions, impacting the body's capacity for blood clotting or leading to other bone marrow disorders.

What the gene does

The protein produced by the MPL gene, the thrombopoietin receptor, is a cell surface receptor that binds to thrombopoietin (TPO). TPO is a hormone that stimulates platelet formation. When TPO attaches to the MPL receptor, an intracellular signalling pathway called the JAK/STAT pathway is activated. This process sends chemical signals into the cell's nucleus, which promotes the growth, division, and differentiation of various blood cell precursors, especially megakaryocytes. These megakaryocytes then mature to create platelets, which are crucial for normal blood clotting. The thrombopoietin receptor is also believed to contribute to the maintenance of haematopoietic stem cells, which are progenitor cells that can develop into all types of blood cells.

Video: Genetics 101

Chromosome location

The MPL gene is situated on the short (p) arm of chromosome 1 at position 34.2, specifically 1p34.2. This genomic location dictates where the gene resides within the human genome and contributes to its expression patterns.

Protein structure

The MPL protein is composed of 635 amino acids and features several distinct structural elements. It includes two Fibronectin type-III domains: Fibronectin type-III 1, located between amino acids 172-281, and Fibronectin type-III 2, spanning amino acids 392-486. A Disordered region is found within amino acids 205-232. Additionally, the protein contains key functional motifs, including the WSXWS motif (amino acids 474-478) and the Box 1 motif (amino acids 528-536), which are important for receptor activation and signalling.

Domain map · 635 amino acids
Fibronectin type-III 1 (172-281)Fibronectin type-III 2 (392-486)WSXWS motif (474-478)Box 1 motif (528-536)Fibronectin type-III 1172-281Fibronectin type-III 2392-486Box 1 motif528-5361~318635
Domain - independent functional unit
Motif - short conserved sequence
🧬 Explore 3D structure on AlphaFold
UniProt:P40238Length:635 aaStructure:AlphaFold

Key variants

Variants within the MPL gene can alter the structure or function of the thrombopoietin receptor, leading to a range of clinical presentations. These genetic changes can affect how the receptor binds to thrombopoietin or how it transmits signals inside the cell, influencing blood cell production. Different types of variants may result in either reduced or enhanced receptor activity, correlating with distinct haematological conditions.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for MPL.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1033C>T
single nucleotide variant
p.Gln345Ter Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.1145del
Deletion
p.Pro382fs Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.11G>A
single nucleotide variant
p.Trp4Ter Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.139del
Deletion
p.Asp47fs Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia 1
c.1469-2A>T
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.1545G>A
single nucleotide variant
p.Trp515Ter Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia 1
c.1671dup
Duplication
p.Asp558fs Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.209del
Deletion
p.Pro70fs Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia 1
c.292C>T
single nucleotide variant
p.Gln98Ter Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia
c.407C>T
single nucleotide variant
p.Pro136Leu Pathogenic/Likely pathogenic ★★☆☆ Congenital amegakaryocytic thrombocytopenia

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in the MPL gene are associated with inherited conditions affecting blood cell production. One such condition is Congenital amegakaryocytic thrombocytopenia, a rare autosomal recessive disorder characterised by very low numbers of megakaryocytes and platelets, which can lead to bone marrow failure. Other conditions like essential thrombocythaemia and primary myelofibrosis, primarily linked to acquired variants, can also involve MPL.

Inheritance pattern

Conditions caused by pathogenic MPL variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous MPL carrier status across ancestry groups?

UK clinical status

The MPL gene is included in several NHS Genomic Medicine Service national test panels. These panels are used for diagnosing and managing conditions related to blood disorders. Specifically, MPL is part of the 'Bleeding and platelet disorders', 'Cytopenia - NOT Fanconi anaemia', 'Cytopenias and congenital anaemias', 'Inherited bleeding disorders', and 'Thrombocythaemia' green R-panels.

Frequently asked questions

What is the primary function of the MPL gene?

The MPL gene provides instructions for the thrombopoietin receptor, which is crucial for the proliferation of megakaryocytes, the cells that produce platelets necessary for blood clotting.

What is Congenital amegakaryocytic thrombocytopenia?

Congenital amegakaryocytic thrombocytopenia is a rare inherited condition caused by MPL variants, characterised by a severe deficiency of megakaryocytes and platelets from birth, which can lead to bone marrow failure.

How does the thrombopoietin receptor work?

The thrombopoietin receptor activates the JAK/STAT signalling pathway upon binding with thrombopoietin, which then stimulates the growth and differentiation of blood cells, especially those involved in platelet formation.

References

  1. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010. PMID: 20428194
  2. Ding J, Komatsu H, Iida S. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009. PMID: 19483125
  3. Chaligné R, Tonetti C, Besancenot R. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008. PMID: 18528423
  4. Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Human mutation. 2006. PMID: 16470591
  5. Pikman Y, Lee BH, Mercher T. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine. 2006. PMID: 16834459
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 18 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .